- Biopharma News

CPhI Report - Pharmaceutical Trend Outlook 2021

Gareth Carpenter — 25 Nov 2020

Twelve emerging market trends we anticipate across 2021 for the pharmaceutical manufacturing and outsourcing sectors

2020 has been one of the most turbulent years in recent history and has cast a shroud of uncertainty over the future. While pharmaceutical companies have proved instrumental in responding to the pandemic through innovation, collaboration and manufacturing expertise, COVID-19 has also raised fresh challenges for the industry to overcome.

In this report, we explore the key opportunities, disruptors and dynamics which the industry will face throughout 2021.

Pharma’s response to the pandemic in terms of vaccines development and distribution of treatments has grabbed the majority of the headlines but the major issues facing the industry are by no means exclusively coronavirus related.

In interviews with key industry experts, this report identifies key trends that we anticipate throughout 2021, as pharmaceutical manufacturing and outsourcing continue to respond not only to the challenges that the ongoing global crisis has presented, but also to evolving obstacles and hurdles that are typical in such a highly-regulated sector.

Here are our top 12 pharmaceutical market trends for 2021:

Supply chain resilience to take precedence over reshoring of API manufacturing
Pandemic accelerates digital transformation of API sourcing and trading
Suppy chain security and patient focus
Cure vs. treatment model shifts CDMO contracts from volume to value
A gradual breakthrough for continuous manufacturing of APIs
COVID-19 vaccines to take central stage
Vaccine distribution and roll-out
Industry fight against antimicrobial resistance to gain prominence
Enablers of precision medicine: next-generation sequencing
Continuing consolidation in the CDMO sector
Emerging pharma markets will be key to expansion of pharma and biopharma capabilities
Rise in biosimilar applications due to patent 12 expiries